BTBR.Cg-Lep^ob/WiscJ

Stock No:: 004824 |; BTBR obese

Available Now

Overview

Also Known As: BTBR obese

These ob/ob mice on a BTBR background are diabetic, severely hyperglycemic and obese, with increased triglycerides.

Genetic overview

Genetic Background	Generation
002282 BTBR T⁺ Itpr3^tf/J	N8F1+N5F10F19 (2019-06-12 00:00:00)

Lep^ob

Allele Type	Gene Symbol	Gene Name
Spontaneous (Null/Knockout)	Lep	leptin

View Genetics

Research Applications

Reproductive Biology Research
Mouse/Human Gene Homologs
Diabetes and Obesity Research
Endocrine Deficiency Research
Immunology, Inflammation and Autoimmunity Research
Internal/Organ Research
Cardiovascular Research
Metabolism Research

View All Research Applications

Base Price

Starting at:

$230.00 Domestic price for female 4-week

View Price List

Details

Detailed Description

Mice homozygous for the obese spontaneous mutation, (Lep^ob commonly referred to as ob or ob/ob) exhibit obesity hyperphagia, a diabetes-like syndrome of hyperglycemia, glucose intolerance, elevated plasma insulin, subfertility, impaired wound healing, and an increase in hormone production from both pituitary and adrenal glands. They are also hypometabolic and hypothermic. The obesity is characterized by an increase in both number and size of adipocytes. Although hyperphagia contributes to the obesity, homozygotes gain excess weight and deposit excess fat even when restricted to a diet sufficient for normal weight maintenance in lean mice. Hyperinsulinemia does not develop until after the increase body weight and is probably the result of it. Homozygotes do have an abnormally low threshold for stimulation of pancreatic islet insulin secretion even in very young preobese animals. As is the case with mice carrying the diabetes mutation (Lepr^db), manifestation of the diabetic syndrome is strikingly dependent on genetic background. Lep^ob homozygotes on the BTBR background develop diabetes at six weeks (males), and eight weeks (females). Hyperglycemia is severe and progressive with a fasting plasma glucose of 400 mg/dl at 10 weeks (Stoehr et al., 2000). In contrast to homozygotes on the C57BL/6 background, BTBR homozygotes develop extreme obesity (Stoehr et al., 2004) and progressive hypertriglyceridemia (Lan et al., 2003). Hepatic lipogenesis is not increased and homozygotes do not develop hepatic steatosis (Lan et al., 2003). Males remain hyperinsulinemic although insulin levels and islet mass are much reduced (Stoehr personal communication). Two modifier loci (Mobe1, Mobe2, formerly, Moo1 and Moo2) regulate total fat mass. BTBR alleles of these loci semi-dominantly increase body mass (Stoehr et al., 2004).

Development

The obese mutation, ob, arose spontaneously at The Jackson Laboratory, Bar Harbor, Maine in 1949. The ob allele from B6.V-Lep^ob/J was introgressed into BTBR T⁺ tf/J using a marker-assisted backcrossing program for six generations at the University of Wisconsin, Madison (Stoehr, 2000). The donating investigator reports that no C57BL/6J alleles were detected with the exception of a 20 cM region on chromosome 6 flanking the leptin locus. Heterozygotes were intercrossed to produce mice homozygous for ob. This strain was donated to The Jackson Laboratory in 2003 and the backcross will be continued to N10.
In 2019, the live colony had been backcrossed to the BTBR inbred strain (Stock No. 002282) for a total of 13 generations and then intercrossed together for at least 18 generations.

Control Suggestions

Wild-type from the colony

Additional Information

Considerations for Choosing Controls

Selected References

Hudkins KL; Pichaiwong W; Wietecha T; Kowalewska J; Banas MC; Spencer MW; Muhlfeld A; Koelling M; Pippin JW; Shankland SJ; Askari B; Rabaglia ME; Keller MP; Attie AD; Alpers CE. 2010. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 21(9):1533-42PubMed: 20634301 MGI: J:185261
Stoehr JP; Nadler ST; Schueler KL; Rabaglia ME; Yandell BS; Metz SA; Attie AD. 2000. Genetic obesity unmasks nonlinear interactions between murine type 2 diabetes susceptibility loci Diabetes 49(11):1946-54PubMed: 11078464 MGI: J:65486
Stoehr JP; Byers JE; Clee SM; Lan H; Boronenkov IV; Schueler KL; Yandell BS; Attie AD. 2004. Identification of major quantitative trait loci controlling body weight variation in ob/ob mice. Diabetes 53(1):245-9PubMed: 14693723 MGI: J:87998

View All References

Genetics

Lep^ob

Allele Symbol: Lep^ob

Allele Name	obese
Allele Type	Spontaneous (Null/Knockout)
Allele Synonym(s)	Lep^ob; obese
Gene Symbol and Name	Lep, leptin
Gene Synonym(s)	OB; OBS; LEPD; ob; obese; obese
Strain of Origin	STOCK Mlph^ln a Tgfa^wa1 Cdh23^v Ednrb^s
Chromosome	6
Molecular Note	Sequencing of RT-PCR products revealed a nonsense mutation in codon 105 resulting from a C to T point mutation. The 16 kDa leptin protein, expressed predominantly in adipose tissue of normal mice, is missing from homozygous mutant mice (J:29081).

Disease/Phenotype

Disease Terms

Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).

Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Lep^ob related

Reproductive Biology Research
- Fertility Defects
Mouse/Human Gene Homologs
- obesity, severe, due to leptin deficiency (rare)
Diabetes and Obesity Research
- Obesity With Diabetes
- Impaired Wound Healing
- Insulin Resistance
- Hyperinsulinemia
Endocrine Deficiency Research
- Adipose Defects
- Hypothalamus/Pituitary Defects
- Pancreas Defects
Immunology, Inflammation and Autoimmunity Research
- Immunodeficiency Associated with Other Defects
Internal/Organ Research
- Adipose Defects
Metabolism Research

Cardiovascular Research
- Hypertriglyceridemia

Mammalian Phenotype Terms by Genotype

The following phenotype information is associated with a similar, but not exact match to this JAX^® Mice strain

Genotype: Lep^ob/Lep^ob
involves: C57BL/6J

adipose tissue phenotype

increased fat cell size
- increase in area size of epigonadal fat cells

increased gonadal fat pad weight
- increase in epigonadal fat tissue weight

increased inguinal fat pad weight

increased interscapular fat pad weight

increased percent body fat/body weight
- increase in fat mass at 8 and 16 weeks of age

cardiovascular system phenotype

abnormal cardiovascular system physiology
- attenuated heart response to increased calcium
- oxygen consumption is elevated when perfused with glucose and palmitate
- oxygen consumption of the heart does not increase with an increased workload

abnormal retinal vasculature morphology
- neovascularization is significantly suppressed under standard oxygen conditions relative to controls

increased heart weight
- heart weight elevated relative to controls

cellular phenotype

abnormal osteoclast differentiation
- increased numbers of osteoclasts

abnormal respiratory electron transport chain
- increased ADP dependent mitochondrial respiration in glucose and palmitate perfused hearts
- mitochondrial respiration is inhibited in glucose perfused hearts
- mitochondrial respiration is uncoupled in glucose and palmitate perfused hearts

digestive/alimentary phenotype

abnormal colon goblet cell morphology
- increased number of mucus filled goblet cells in the colon

abnormal intestinal mucosa morphology
- thick mucus gel covers the epithelium of the colon

endocrine/exocrine gland phenotype

abnormal colon goblet cell morphology
- increased number of mucus filled goblet cells in the colon

abnormal insulin secretion
- acetyl choline has a greater affect to lower the glucose induced threshold for insulin secretion
- lower threshold for glucose induced insulin secretion by beta cells

enlarged pancreatic islets
- increase in the size of islets of Langerhans and appearance of enormous islets in the pancreas of 30 week old mice

growth/size/body region phenotype

abnormal postnatal growth
- pair fed mice gain considerably more weight as fat than controls eating the same quantity of food
- pair fed mice gain less weight as protein than when feeding is unrestricted
- pair fed mice gain less weight than when feeding is unrestricted
- pair fed mice restrict food intake to that of controls

increased body length

increased lean body mass
- increase in lean mass at 8 and 16 weeks of age

obese
- increase in weight gain in a short period of time

hematopoietic system phenotype

abnormal osteoclast differentiation
- increased numbers of osteoclasts

homeostasis/metabolism phenotype

abnormal corticosterone level
- corticosterone response to stress greater than in controls
- diurnal variation greater than in controls

abnormal glucose homeostasis

abnormal hormone level

abnormal insulin secretion
- acetyl choline has a greater affect to lower the glucose induced threshold for insulin secretion
- lower threshold for glucose induced insulin secretion by beta cells

hyperglycemia

impaired glucose tolerance
- observed prior to any significant increase in body weight

increased adrenocorticotropin level
- levels in the pituitary are much higher than in pituitaries of controls

increased circulating corticosterone level
- severe

increased circulating insulin level

increased fasting circulating glucose level
- fasting mice show increased glucose levels at 6 weeks of age

insulin resistance
- in the insulin tolerance test, mice reduce their glucose levels within 30 min to about 80% compared to 50% in wild-type mice at 6 weeks of age
- mice do not respond to insulin in the insulin tolerance test at 15 weeks of age, indicating insulin resistance

immune system phenotype

abnormal osteoclast differentiation
- increased numbers of osteoclasts

integument phenotype

abnormal epidermal layer morphology
- significant reduction in intraepidermal nerve fiber density

increased thermal nociceptive threshold
- 88% increased latency of hind-limb withdrawal from a heat stimulus

liver/biliary system phenotype

hepatic steatosis

increased liver weight

mortality/aging

postnatal lethality, incomplete penetrance
- 50 % higher postnatal death rate of males

muscle phenotype

abnormal muscle contractility
- basal calcium ion concentration increases sharply toward the end of a series of 50 tetanic contractions (single cell measures)
- number of tetani required to reduce force by 40% is significantly less than for controls

nervous system phenotype

decreased nerve conduction velocity
- 16% lower motor nerve conduction velocity than controls
- hind limb sensory nerve conduction velocity reduced 22%

skeleton phenotype

abnormal osteoclast differentiation
- increased numbers of osteoclasts

abnormal skeleton development
- rate of new bone formation increased at both 3 and 6 months

increased bone mass
- denser vertebrae and long bones at 6 months
- increased bone mass even on a low fat diet to delay obesity

osteopetrosis
- 2 fold increase in trabecular bone volume
- increased numbers of thick trabeculae at 3 and 6 months

vision/eye phenotype

abnormal retinal vasculature morphology
- neovascularization is significantly suppressed under standard oxygen conditions relative to controls

behavior/neurological phenotype

abnormal behavior
- faster in food finding trials relative to controls

hypoactivity

increased thermal nociceptive threshold
- 88% increased latency of hind-limb withdrawal from a heat stimulus

polyphagia
- mice eat twice as much as wild-type mice

Genotype: Lep^ob/Lep^ob
B6.Cg-Lep/J

adipose tissue phenotype

abnormal epididymal fat pad morphology
- adipocyte size remains larger after treatment with triiodothyronine relative to controls
- treatment with triiodothyronine significantly reduces epididymal fat pad weight relative to the degree of reduction seen in controls

decreased white fat cell number
- treatment with triiodothyronine reduces adipocyte numbers
- treatment with triiodothyronine significantly reduces adipocyte numbers relative to the degree of reduction seen in controls

increased fat cell size

increased interscapular fat pad weight
- affected less by treatment with triiodothyronine than controls
- brown adipocyte numbers are normal
- greater weight than for controls

increased percent body fat/body weight
- mice have fat mass of ~42 g compared to ~3 g in wild-type at 16 weeks

behavior/neurological phenotype

abnormal food intake

abnormal frequency of paradoxical sleep
- increased REM in dark phase
- reduced REM in light phase

abnormal pain threshold

abnormal sleep pattern
- additional sleep primarily in the dark phase
- increased non-REM sleep time
- increased total sleep time in a 24 hour period
- recovery from sleep deprivation involves increased duration of non-REM bouts rather than increased number of bouts as seen in controls

allodynia
- epineural application of leptin treated peritoneal macrophage induces tactile allodynia
- resistant to tactile allodynia caused by partial sciatic nerve ligation

decreased food intake
- food intake is reduced by Leptin treatment

fragmentation of sleep/wake states
- more arousals
- shorter wake periods
- sleep more fragmented

hyperalgesia
- display thermal hyperalgesia after partial sciatic nerve ligation

hypoactivity
- less wheel running activity
- more wheel running activity in light phase and less in dark phase
- significantly reduced activity relative to wild-type controls

increased food intake
- increased food intake when ambient temperature drops from 28 to 21C

polyphagia
- mice eat 70% more than wild-type controls

integument phenotype

abnormal pain threshold

allodynia
- epineural application of leptin treated peritoneal macrophage induces tactile allodynia
- resistant to tactile allodynia caused by partial sciatic nerve ligation

hyperalgesia
- display thermal hyperalgesia after partial sciatic nerve ligation

liver/biliary system phenotype

abnormal liver weight
- treatment with triiodothyronine significantly reduces relative and absolute liver weight

muscle phenotype

abnormal muscle morphology
- muscle protein content is reduced

abnormal myocardial fiber morphology
- cardiomyocytes exhibit a significantly enlarged cross-sectional area
- exhibit extensive focal damage in myocardial tissue, showing an abundance of lipid droplets in myocytes and damaged mitochondria that are swelled, have disorganized cristae and show loss of integrity
- exhibit myocyte hypertrophy, with increased myocyte diameter and distorted nuclear architecture

abnormal skeletal muscle fiber type ratio
- lower proportion of faster myosin heavy chain isoforms

decreased cardiac muscle contractility
- cardiomyocytes exhibit a reduced contractile capacity
- decreased peak shortening
- elevated resting peak calcium ion concentration
- exhibit cardiac contractile dysfunction that is due to leptin deficiency and not obesity as high fat diet-induced obese controls show normal cardiomyocyte morphology and contractile function
- prolonged relengthening
- slowed intracellular calcium ion decay

decreased skeletal muscle fiber size
- cross-sectional area of muscle fibers is generally smaller

decreased skeletal muscle mass
- mean muscle mass consistently less than controls but magnitude of difference is muscle specific

enlarged myocardial fiber
- cardiomyocytes display larger resting cell length and cross-sectional area

heart left ventricle hypertrophy
- increase in left ventricle wall thickness and mass is seen by 6 months of age but not at 2 months of age
- induced weight loss via leptin infusion, but not via caloric restriction, partially resolves the hypertrophy

neoplasm

increased metastatic potential
- increased metastasis to the lung of both melanoma cell lines and lung cancer cell lines initially injected in the tail vein
- leptin reduces the level of metastasis

nervous system phenotype

abnormal sympathetic nervous system physiology

renal/urinary system phenotype

abnormal urine catecholamine level
- less epinephrine in the urine of ad libitum fed mice
- males show elevated levels of dopamine in urine
- urine levels of norepinephrine only slightly elevated

abnormal urine homeostasis
- males show elevated levels of serotonin and 5'hydroxyindolineacetic acid in urine

reproductive system phenotype

female infertility
- females do not produce litters

respiratory system phenotype

lung inflammation
- ozone induces a nonsignificant elevation of TNFR2 levels
- ozone induces significantly elevated levels of TNFR1

skeleton phenotype

abnormal bone marrow morphology
- bone marrow is almost completely replaced with mature adipocytes

cardiovascular system phenotype

abnormal myocardial fiber morphology
- cardiomyocytes exhibit a significantly enlarged cross-sectional area
- exhibit extensive focal damage in myocardial tissue, showing an abundance of lipid droplets in myocytes and damaged mitochondria that are swelled, have disorganized cristae and show loss of integrity
- exhibit myocyte hypertrophy, with increased myocyte diameter and distorted nuclear architecture

abnormal myocardial fiber physiology
- cardiomyocytes exhibit decreased peak shortening and maximal velocity of shortening/relengthening, prolonged time-to-90% relengthening, reduced intracellular calcium release upon electrical stimulus associated with a slowed intracellular calcium decay rate, and significantly higher oxygen levels
- e, and significantly higher oxygen levels

decreased cardiac muscle contractility
- cardiomyocytes exhibit a reduced contractile capacity
- decreased peak shortening
- elevated resting peak calcium ion concentration
- exhibit cardiac contractile dysfunction that is due to leptin deficiency and not obesity as high fat diet-induced obese controls show normal cardiomyocyte morphology and contractile function
- prolonged relengthening
- slowed intracellular calcium ion decay

enlarged myocardial fiber
- cardiomyocytes display larger resting cell length and cross-sectional area

heart left ventricle hypertrophy
- increase in left ventricle wall thickness and mass is seen by 6 months of age but not at 2 months of age
- induced weight loss via leptin infusion, but not via caloric restriction, partially resolves the hypertrophy

endocrine/exocrine gland phenotype

abnormal pancreatic beta cell physiology
- Background Sensitivity - less beta cell degranulation than seen on the "BKS" background

decreased insulin secretion
- leptin-treated islet cells exhibit decreased insulin secretion compared to similarly treated wild-type islets

enlarged pancreatic islets

increased insulin secretion
- insulin content in the pancreata is increased compared to in wild-type mice

growth/size/body region phenotype

abnormal body weight
- body weight reduced by treatment with Leptin
- treatment with triiodothyronine significantly reduces body weight relative to the reduction seen in controls

increased body weight

increased growth rate
- mice reach 60-70 g by 10 months of age

obese
- 12-week old males are obese
- develop progressive obesity

hematopoietic system phenotype

decreased NK cell number
- reduced numbers can be restored by treatment with leptin

homeostasis/metabolism phenotype

abnormal circulating cholesterol level

abnormal circulating glucose level

abnormal oxygen consumption
- increased by treatment with triiodothyronine
- insulin stimulated oxygen consumption by the soleus muscle is little affected by triiodothyronine
- oxygen consumption about 2/3 that observed in controls

abnormal protein level
- total body protein increased by treatment with triiodothyronine
- total body protein lower than in controls

abnormal urine catecholamine level
- less epinephrine in the urine of ad libitum fed mice
- males show elevated levels of dopamine in urine
- urine levels of norepinephrine only slightly elevated

abnormal urine homeostasis
- males show elevated levels of serotonin and 5'hydroxyindolineacetic acid in urine

decreased body temperature
- body temperature is maintained a basal level when the ambient temperature is gradually reduced to 4C

decreased circulating glucose level
- 4 weeks' treatment with Adipor2-ASO (antisense oligonucleotide) significantly reduces plasma glucose levels in fed mice
- after feeding, serum glucose levels are more than 30% lower than in wild-type mice
- when treated with AdipoR2-ASO, mice exhibit a decrease in plasma glucose level

decreased insulin secretion
- leptin-treated islet cells exhibit decreased insulin secretion compared to similarly treated wild-type islets

decreased oxygen consumption
- in the epididymal and brown fat pads

hyperglycemia
- Background Sensitivity - blood glucose levels are lower than obese mice on the BTBR background
- blood sugar peaks at 2-3 months
- Background Sensitivity - homozygotes exhibit a mild, transient hyperglycemia between 10-14 weeks of age as compared to the severe, progressive hyperglycemia observed on the BTBR background
- males exhibit elevated blood glucose levels (254.4 +/-33.7 mg/dl) as compared to wild-type between 20-22 weeks of age
- mice infrequently transition to severe hyperglycemia
- returns to normal by 4-5 months of age
- serum glucose is 320 mg/dl compared to 134 mg/dl in wild-type controls
- transient hyperglycemia

hypoglycemia
- older mice are usually hypoglycemic

impaired glucose tolerance
- following an acute intraperitoneal glucose injection, the post-challenge glucose level remained elevated up to 120 min compared to controls, indicating glucose intolerance
- glucose intolerance which improved when treated with rosiglitazone

increased circulating cholesterol level
- fasting plasma total cholesterol concentration is increased 2-3 fold over controls

increased circulating HDL cholesterol level

increased circulating insulin level
- at 2 weeks, insulin levels are increased 2.5-fold compared to in wild-type mice
- Normal - however, mice treated with isoproterenol exhibit lowered serum levels of insulin
- insulin levels increase rapidly to over 50X normal controls
- seen in 12-week old males
- serum insulin is 41.5 ng/ml compared to 0.8 ng/ml in wild-type

increased circulating LDL cholesterol level

increased circulating triglyceride level
- seen in 12-week old males
- triglyceride levels are elevated 1.5- to 2-fold

increased circulating VLDL cholesterol level

increased insulin secretion
- insulin content in the pancreata is increased compared to in wild-type mice

increased oxygen consumption
- in the liver

insulin resistance

immune system phenotype

decreased NK cell number
- reduced numbers can be restored by treatment with leptin

lung inflammation
- ozone induces a nonsignificant elevation of TNFR2 levels
- ozone induces significantly elevated levels of TNFR1

Genotype: Lep^ob/Lep^ob
D2.Cg-Lep/Chua

endocrine/exocrine gland phenotype

abnormal pancreatic islet morphology
- islets of mutants with low insulin levels are abnormal in appearance, being found in clusters of 1-4 cells, scattered within the ductal epithelium

decreased pancreatic beta cell number
- mutants with low insulin secretion have a low number of insulin-secreting cells compared to controls or high-insulin secreting mutants

increased pancreatic beta cell number
- there is a 5-fold increase in number of insulin-secreting cells per islet in obese mice with high insulin secretion

growth/size/body region phenotype

obese

homeostasis/metabolism phenotype

hyperglycemia
- at 3 months of age, males are hyperglycemic with blood glucose levels of ~574 mg/dl; females have levels of ~388 mg/dl

increased circulating insulin level
- some mutant DBA/2J mice have high insulin levels compared to controls

Genotype: Lep^ob/Lep^ob
FVB.Cg-Lep/Chua

homeostasis/metabolism phenotype

hyperglycemia
- mice are hyperglycemic like congenic FVB Lepr mice

increased circulating insulin level
- mice are hyperinsulinemic like congenic FVB Lepr^db mice

Genotype: Lep^ob/Lep^ob
involves: 129X1/SvJ * C57BL/6

adipose tissue phenotype

abnormal adipose tissue amount
- combined white adipose tissue (WAT) mass is increased compared to wild-type

growth/size/body region phenotype

decreased lean body mass
- decreased (16.0 g, 33% of body weight) compared to wild-type (25.5 g 87% of body weight) or double mutants (19.8g)

increased body weight
- higher than wild-type

homeostasis/metabolism phenotype

abnormal circulating hormone level

abnormal circulating pancreatic peptide level
- plasma levels of pancreatic polypeptide (PP) are strongly reduced compared to wild-type

decreased circulating testosterone level
- level is markedly decreased compared to wild-type or Lep heterozygotes
- significantly lower (4.2 nmol/l) compared to wild-type (14.2 nmol/l)

hyperglycemia

increased circulating cholesterol level
- 5.74 mmol/l vs 3.54 mmol/l in wild-type

increased circulating corticosterone level
- mice display hypercorticosteronemia compared to wild-type
- mice display hypercorticosteronemia compared to wild-type, Npy2r^tm1.1Hhz homozygotes, or Npy2r, Lep double mutants

increased circulating insulin level
- hyperinsulinemic compared to wild-type
- level is significantly increased over wild-type

increased circulating leptin level
- level is significantly increased over wild-type

increased circulating triglyceride level
- 2.48 mmol/l vs 1.62 mmol/l in wild-type

behavior/neurological phenotype

polyphagia

integument phenotype

abnormal branching of the mammary ductal tree
- in virgin females, no ductal development occurs

liver/biliary system phenotype

increased liver weight
- 4.56 g vs 1.44 g in wild-type

renal/urinary system phenotype

increased kidney weight
- 0.54 g vs 0.41 g in wild-type

reproductive system phenotype

abnormal ovarian folliculogenesis
- ovaries have very few primary or secondary follicles

abnormal vagina orifice morphology
- vaginal opening is very small compared to wild-type

absent corpus luteum
- no corpora lutea develops properly in ovary

decreased seminal vesicle weight
- weight of gland is significantly lower than wild-type or heterozygotes

decreased testis weight
- testes weigh 0.19 g compared to 0.33 g in wild-type
- testis weight is significantly lower than in Lep^ob heterozygotes or Lep, Ppyr1 double null mice

female infertility
- homozygous females produce no litters

male infertility
- no males could produce offspring
- only one male tested was able to sire a litter

prolonged diestrus
- mice have diestrous-like swab until 9 weeks of age

prolonged estrous cycle
- beginning at 9 weeks of age, estrous cycles last 11-15 days

prolonged estrus
- beginning at 9 weeks of age, estrous-like cytology lasts 6-8 days

digestive/alimentary phenotype

abnormal intestine morphology
- mice display intestinal hypertrophy compared to wild-type mice (intestine weight - 1.89 g vs 1.03 g in wild-type; intestine length 43 cm vs 33 cm in wild-type)

endocrine/exocrine gland phenotype

abnormal branching of the mammary ductal tree
- in virgin females, no ductal development occurs

abnormal ovarian folliculogenesis
- ovaries have very few primary or secondary follicles

absent corpus luteum
- no corpora lutea develops properly in ovary

decreased seminal vesicle weight
- weight of gland is significantly lower than wild-type or heterozygotes

decreased testis weight
- testes weigh 0.19 g compared to 0.33 g in wild-type
- testis weight is significantly lower than in Lep^ob heterozygotes or Lep, Ppyr1 double null mice

increased pancreas weight
- 0.41 g vs 0.29 in wild-type

Genotype: Lep^ob/Lep⁺
involves: 129X1/SvJ * C57BL/6

liver/biliary system phenotype

increased liver weight
- mice show significant increase in relative and absolute hepatic weight compared to wild-type; otherwise, no differences from wild-type are noted

Genotype: Lep^ob/Lep^ob
involves: 129 * C57BL/6

adipose tissue phenotype

increased percent body fat/body weight
- 40% increase compared to wild-type at 20 weeks

homeostasis/metabolism phenotype

abnormal lipid level
- sphingomeylin and antioxidant ethanolamine plasmlogen are markedly decreased

increased circulating insulin level
- at 4 and 16 weeks of age

increased insulin secretion
- at 16 weeks of age

insulin resistance
- at 16 weeks

liver/biliary system phenotype

hepatic steatosis

behavior/neurological phenotype

hypoactivity
- at 20 weeks, mice have decreased locomotor activity compared to wild-type

polyphagia
- hyperphagic

endocrine/exocrine gland phenotype

abnormal pancreatic islet morphology
- at 16 weeks, increased islet-to-pancreases volume ratios
- at 16 weeks, islet insulin content is 30-fold greater than in Pparg^tm1Avb Lep^ob homozygotes

enlarged pancreatic islets

increased insulin secretion
- at 16 weeks of age

increased pancreatic islet number

growth/size/body region phenotype

increased body weight
- mice quickly become heavier and have significantly elevated body weights at 4 and 6 weeks of age in females and males, respectively

Genotype: Lep^ob/Lep^ob
BKS.Cg-Lep/J

endocrine/exocrine gland phenotype

abnormal pancreatic beta cell physiology
- Background Sensitivity - more beta cell degranulation than seen on the 'B6' background

small pancreatic islets
- after 2 months, islets become smaller and atrophic

mortality/aging

premature death

renal/urinary system phenotype

increased urine glucose level

polyuria

growth/size/body region phenotype

increased growth rate
- mice reach 45-55 g by 3-4 months of age
- slowly lose weight from 4 months on

homeostasis/metabolism phenotype

abnormal circulating cholesterol level

abnormal circulating glucose level

hyperglycemia
- blood sugar continues to rise
- blood sugar never returns to control levels
- stabilizes at around 400-500 mg/100 ml

increased circulating cholesterol level
- fasting plasma total cholesterol concentration is increased 2-3 fold over controls

increased circulating HDL cholesterol level

increased circulating insulin level
- insulin levels increase only through the first 2 months
- levels drop back to normal

increased circulating LDL cholesterol level

increased circulating triglyceride level
- triglyceride levels are elevated 1.5- to 2-fold

increased circulating VLDL cholesterol level

increased urine glucose level

Genotype: Lep^ob/Lep^ob
B6.Cg-Lep/OlaHsd

digestive/alimentary phenotype

abnormal digestive system physiology
- transepithelial resistance in the epithelium is reduced, indictive of a disrupted mucosal barrier function

abnormal intestinal epithelium morphology
- reduced levels of occludin in intestinal sections
- zonula occludens 1 has a discontinuous distribution

immune system phenotype

abnormal acute inflammation
- higher levels of endotoxin are found in portal blood (entotoxemia)

abnormal chemokine secretion
- increased release of monocyte chemo attractant protein by hepatic stellate cells

increased interleukin-6 secretion
- increased release by hepatic stellate cells

increased susceptibility to endotoxin shock
- increased succeptibility of hepatic stellate cells to LPS

liver inflammation

liver/biliary system phenotype

liver inflammation

Genotype: Lep^ob/Lep⁺
involves: C57BL/6J

skeleton phenotype

increased bone mass
- increased bone mass even on a low fat diet to delay obesity

Genotype: Lep^ob/Lep^ob
B6.Cg-Lep/JBomTac

homeostasis/metabolism phenotype

increased circulating triglyceride level
- 3-fold

Genotype: Lep^ob/Lep^ob
involves: STOCK Mlph a Tgfa Cdh23 Ednrb

adipose tissue phenotype

abnormal fat cell morphology
(MGI Ref ID J:5253)
hyperplasia
(MGI Ref ID J:7702)

increased fat cell size
(MGI Ref ID J:7702)

embryo phenotype

abnormal embryonic neuroepithelium morphology
cell proliferation is lower at E14 and E16
(MGI Ref ID J:105139)
significantly fewer cells at E16 and E18 but not at E14
(MGI Ref ID J:105139)

decreased embryonic neuroepithelium thickness
thin at E18
(MGI Ref ID J:105139)

endocrine/exocrine gland phenotype

abnormal gland physiology
(MGI Ref ID J:7702)

abnormal pancreatic beta cell morphology
(MGI Ref ID J:7702)

decreased activity of thyroid gland
(MGI Ref ID J:7702)

hypersecretion of corticosterone
increased glucocorticoids from the adrenal
(MGI Ref ID J:7702)

increased pancreatic beta cell mass
increased size
(MGI Ref ID J:7702)

increased pancreatic beta cell number
(MGI Ref ID J:7702)

growth/size/body region phenotype

decreased body length
expansive hind quarters
(MGI Ref ID J:13066)
first noticeable at 4-6 weeks of age
(MGI Ref ID J:13066)
short body
(MGI Ref ID J:13066)
square shape
(MGI Ref ID J:13066)

increased body weight
(MGI Ref ID J:159285)

increased growth rate
begin to gain weight rapidly by 4-6 weeks of age
(MGI Ref ID J:13066)
weigh 75-90g at 10 months
(MGI Ref ID J:13066)
weigh twice as much as controls at 3 months of age
(MGI Ref ID J:13066)

hematopoietic system phenotype

abnormal microglial cell physiology
30-40% as many activated microglia 5 days after kainic acid treatment as for controls
(MGI Ref ID J:115569)
migrate normally to injury sites but do not proliferate
(MGI Ref ID J:115569)

homeostasis/metabolism phenotype

abnormal glucose homeostasis
(MGI Ref ID J:7702)

abnormal hormone level
increased beta endorphin levels
(MGI Ref ID J:7702)
increased levels of melanocyte stimulating hormone
(MGI Ref ID J:7702)

abnormal vascular wound healing
neointimal area increased by leptin injection or adenoviral leptin treatment
(MGI Ref ID J:135034)
reduced neointimal area relative to controls 4 weeks after femoral artery injury
(MGI Ref ID J:135034)
vascular smooth muscle proliferation significantly reduced
(MGI Ref ID J:135034)

altered response to myocardial infarction
mice exhibit a significant decline in cardiac function, and increase in apoptosis and necrosis, and elevated reactive oxygen species generation after myocardial ischemia/reperfusion injury
(MGI Ref ID J:219470)

decreased body temperature
mice have a lower basal body temperature than controls
(MGI Ref ID J:12010)

decreased circulating tumor necrosis factor level
48% of control levels after kainate injection
(MGI Ref ID J:115569)

decreased liver triglyceride level
lower level than wild-type after 36 hour fasting in 7-week-old mice.
(MGI Ref ID J:199803)

hyperglycemia
transient hyperglycemia
(MGI Ref ID J:7702)

impaired adaptive thermogenesis
60 minute exposure of 17 day old mice to 4C results in a marked drop in body temperature
(MGI Ref ID J:12010)
extreme cold susceptibility
(MGI Ref ID J:7702)
mice acclimated to 12C before exposure survive better to 4C exposure than un-acclimated controls
(MGI Ref ID J:7702)
mice moved directly to 4C from 21C become hypothermic and die
(MGI Ref ID J:7702)

impaired glucose tolerance
(MGI Ref ID J:7702)

increased adrenocorticotropin level
increased pituitary ACTH
(MGI Ref ID J:7702)

increased circulating insulin level
(MGI Ref ID J:7702)

increased liver triglyceride level
double the control littermate's triglyceride level in 7 to 14 weeks old mice
(MGI Ref ID J:199803)

behavior/neurological phenotype

polyphagia
hyperphagia
(MGI Ref ID J:7702)

immune system phenotype

abnormal microglial cell physiology
30-40% as many activated microglia 5 days after kainic acid treatment as for controls
(MGI Ref ID J:115569)
migrate normally to injury sites but do not proliferate
(MGI Ref ID J:115569)

decreased circulating tumor necrosis factor level
48% of control levels after kainate injection
(MGI Ref ID J:115569)

cardiovascular system phenotype

abnormal arteriole morphology
basal arteriolar diameter is greater than controls
(MGI Ref ID J:151096)
potassium-ATP channel inhibition eliminates diameter difference from controls
(MGI Ref ID J:151096)

abnormal vascular wound healing
neointimal area increased by leptin injection or adenoviral leptin treatment
(MGI Ref ID J:135034)
reduced neointimal area relative to controls 4 weeks after femoral artery injury
(MGI Ref ID J:135034)
vascular smooth muscle proliferation significantly reduced
(MGI Ref ID J:135034)

altered response to myocardial infarction
mice exhibit a significant decline in cardiac function, and increase in apoptosis and necrosis, and elevated reactive oxygen species generation after myocardial ischemia/reperfusion injury
(MGI Ref ID J:219470)

limbs/digits/tail phenotype

short femur
(MGI Ref ID J:102535)

short humerus
(MGI Ref ID J:102535)

liver/biliary system phenotype

decreased liver triglyceride level
lower level than wild-type after 36 hour fasting in 7-week-old mice.
(MGI Ref ID J:199803)

decreased susceptibility to hepatic steatosis
after 36 hour fasting in 7-week-old mice
(MGI Ref ID J:199803)

increased liver triglyceride level
double the control littermate's triglyceride level in 7 to 14 weeks old mice
(MGI Ref ID J:199803)

nervous system phenotype

abnormal cortical plate morphology
fewer cells in the cortical plate at E18
(MGI Ref ID J:105139)

abnormal embryonic neuroepithelium morphology
cell proliferation is lower at E14 and E16
(MGI Ref ID J:105139)
significantly fewer cells at E16 and E18 but not at E14
(MGI Ref ID J:105139)

abnormal microglial cell physiology
30-40% as many activated microglia 5 days after kainic acid treatment as for controls
(MGI Ref ID J:115569)
migrate normally to injury sites but do not proliferate
(MGI Ref ID J:115569)

decreased embryonic neuroepithelial cell proliferation
cell proliferation is lower at E14 and E16
(MGI Ref ID J:105139)

decreased embryonic neuroepithelium thickness
thin at E18
(MGI Ref ID J:105139)

reproductive system phenotype

female infertility
homozygous females fail to ovulate
(MGI Ref ID J:7702)

infertility
(MGI Ref ID J:7702)

male infertility
all older males are sterile
(MGI Ref ID J:7702)

reduced male fertility
only 20% of young males are fertile
(MGI Ref ID J:7702)

skeleton phenotype

abnormal long bone epiphyseal plate morphology
breakage at the chondro-osseous junction
(MGI Ref ID J:102535)
failure at a force of 4.9 Newtons as compared to 8.4 Newtons in controls
(MGI Ref ID J:102535)
less organized loose reticular distribution of collagen fibrils
(MGI Ref ID J:102535)
more fragile than controls
(MGI Ref ID J:102535)
reduced expression of "type-X" collagen
(MGI Ref ID J:102535)

abnormal long bone epiphyseal plate proliferative zone
column structure is disturbed
(MGI Ref ID J:102535)
poor alignment
(MGI Ref ID J:102535)

abnormal long bone hypertrophic chondrocyte zone
column structure is disturbed
(MGI Ref ID J:102535)
increased numbers of apoptotic chondrocytes
(MGI Ref ID J:102535)
mostly mineralized as compared to less than 50% mineralized in controls
(MGI Ref ID J:102535)
poor alignment
(MGI Ref ID J:102535)

decreased bone mass
reduced bone mass
(MGI Ref ID J:7702)

decreased length of long bones
(MGI Ref ID J:102535)

short femur
(MGI Ref ID J:102535)

short humerus
(MGI Ref ID J:102535)

Genotype: Lep^ob/Lep^ob
involves: C57BL/6

cellular phenotype

decreased T cell proliferation
(MGI Ref ID J:164339)

immune system phenotype

decreased CD4-positive, alpha beta T cell number
(MGI Ref ID J:164339)

decreased splenocyte number
(MGI Ref ID J:164339)

decreased T cell proliferation
(MGI Ref ID J:164339)

liver/biliary system phenotype

increased liver cholesterol level
livers exhibit slightly, but significantly, higher levels of cholesterol
(MGI Ref ID J:72027)

increased liver triglyceride level
livers exhibit about 10x higher levels of triglyceride
(MGI Ref ID J:72027)

hematopoietic system phenotype

decreased CD4-positive, alpha beta T cell number
(MGI Ref ID J:164339)

decreased splenocyte number
(MGI Ref ID J:164339)

decreased T cell proliferation
(MGI Ref ID J:164339)

homeostasis/metabolism phenotype

increased circulating cholesterol level
seen at 3-4 months of age
(MGI Ref ID J:72027)

increased circulating HDL cholesterol level
slightly elevated at 3 and 8 months of age
(MGI Ref ID J:72027)

increased circulating triglyceride level
seen at 3-4 months of age
(MGI Ref ID J:72027)

increased liver cholesterol level
livers exhibit slightly, but significantly, higher levels of cholesterol
(MGI Ref ID J:72027)

increased liver triglyceride level
livers exhibit about 10x higher levels of triglyceride
(MGI Ref ID J:72027)

Genotype: Lep^ob/Lep^ob
involves: BTBR * C57BL/6 * V stock

endocrine/exocrine gland phenotype

decreased pancreatic beta cell number
severely diabetic mice exhibit reduced numbers of beta cells
(MGI Ref ID J:65486)

disorganized pancreatic islets
moderate to severely diabetic F2 mice have no hyperplasia, but exhibit cellular disorganization and fibrosis
(MGI Ref ID J:65486)
severely diabetic F2 mice exhibit concavities with acinar tissue intrusions
(MGI Ref ID J:65486)

pancreatic islet hyperplasia
mildly diabetic F2 mice exhibit large numbers of hyperplastic pancreatic islets
(MGI Ref ID J:65486)

homeostasis/metabolism phenotype

hyperglycemia
homozygotes exhibit a 7.5 fold range in fasting glucose (100-750 mg/dl)
(MGI Ref ID J:65486)

increased circulating insulin level
homozygotes exhibit a 50 fold range in fasting insulin (2.5-125 ng/ml)
(MGI Ref ID J:65486)

Genotype: Lep^ob/Lep^ob
B6.Cg-Lep/JRj

cellular phenotype

abnormal cell cycle
hepatocytes accumulate in G2 phase in cultures at 60 hours after plating indicating a G2/M arrest
(MGI Ref ID J:220381)
hepatocytes accumulate in S phase at late time points during culture compared to control hepatocytes which exit S phase
(MGI Ref ID J:220381)
Normal - treatment with the antioxidant NAC reduces accumulation of BrdU at 60 hours after plating, indicating normal progression through the cell cycle
(MGI Ref ID J:220381)

oxidative stress
Normal - long-term administration of NAC alleviates oxidative stress in the liver parenchyma
(MGI Ref ID J:220381)
markers of oxidative stress are detectable in hepatocytes both in vitro and in vivo
(MGI Ref ID J:220381)
Normal - treatment with the antioxidant NAC impairs the accumulation of ROS with no impact on cell viability
(MGI Ref ID J:220381)

liver/biliary system phenotype

abnormal hepatocyte physiology
binuclear fraction of hepatocytes is lower in the liver parenchyma
(MGI Ref ID J:220381)
liver contains highly polyploid mononuclear hepatocytes which are infrequently seen in wild-type liver
(MGI Ref ID J:220381)
livers are enriched in hepatocytes with high DNA content compared to controls
(MGI Ref ID J:220381)
the mononuclear diploid (2n) hepatocyte population is lower in the mutant liver than in wild-type liver while mononuclear tetraploid hepatocytes are enriched in the mutant liver
(MGI Ref ID J:220381)
Normal - treatment with the antioxidant NAC restores a normal ploidy profile in mutant cultures
(MGI Ref ID J:220381)

~~The following phenotype relates to a compound genotype created using this strain~~

Genotype: Lep^ob/Lep^ob
BTBR.Cg-Lep

homeostasis/metabolism phenotype

hyperglycemia
Background Sensitivity - homozygotes exhibit severe, progressive hyperglycemia between 10-14 weeks of age as compared to the mild, transient hyperglycemia observed on the C57BL/6 background
(MGI Ref ID J:65486)

Genotype: Lep^ob/Lep^ob
BTBR.Cg-Lep/WiscJ

cardiovascular system phenotype

hypotension
(MGI Ref ID J:185261)

endocrine/exocrine gland phenotype

abnormal pancreatic islet morphology
architecture of islets is disrupted, with many noninsulin staining cells in the central core
(MGI Ref ID J:106121)
whole pancreas insulin content is reduced by 75-80% compared to mutants on the C57BL/6 background
(MGI Ref ID J:106121)

decreased pancreatic beta cell mass
(MGI Ref ID J:106121)

small pancreatic islets
many small islets that show poor insulin staining
(MGI Ref ID J:106121)

mammalian phenotype

cardiovascular system phenotype
Normal - mice do not develop atherosclerosis
(MGI Ref ID J:185261)

renal/urinary system phenotype

abnormal podocyte morphology
reduced podocyte density
(MGI Ref ID J:185261)
reduced podocyte number
(MGI Ref ID J:185261)

albuminuria
albuminuria is detected as early as 8 weeks of age, progressing to a 10-fold difference by 20 weeks of age
(MGI Ref ID J:185261)
increased albumin creatinine ratio
(MGI Ref ID J:185261)

enlarged kidney
renal hypertrophy
(MGI Ref ID J:185261)

expanded mesangial matrix
renal lesions are characterized by increased glomerular mesangial matrix accumulation
(MGI Ref ID J:185261)

glomerulosclerosis
(MGI Ref ID J:185261)

increased kidney weight
both sexes exhibit increased kidney weight as compared to wild-type
(MGI Ref ID J:185261)
kidney weight of males is increased compared to females
(MGI Ref ID J:185261)

increased renal glomerulus basement membrane thickness
glomerular basement membrane thickness is increased by 18% as compared to wild-type
(MGI Ref ID J:185261)

mesangiolysis
diffuse mesangial sclerosis
(MGI Ref ID J:185261)
mesangiolysis increases with age reaching 33.1% by 22 weeks of age
(MGI Ref ID J:185261)
mesangiolysis is observed in 8% of glomeruli 8 week old mice
(MGI Ref ID J:185261)

renal glomerulus hypertrophy
increased glomerular size
(MGI Ref ID J:185261)

renal interstitial fibrosis
focal and mild interstitial fibrosis is observed in 12 week old mice
(MGI Ref ID J:185261)
interstitial collagen accumulation is increased at 24 weeks of age as compared to wild-type
(MGI Ref ID J:185261)

growth/size/body region phenotype

increased body weight
body weight is increased by 8 weeks of age as compared to heterozygotes and wild-type
(MGI Ref ID J:185261)

homeostasis/metabolism phenotype

albuminuria
albuminuria is detected as early as 8 weeks of age, progressing to a 10-fold difference by 20 weeks of age
(MGI Ref ID J:185261)
increased albumin creatinine ratio
(MGI Ref ID J:185261)

hyperglycemia
Background Sensitivity - blood glucose levels are higher than obese mice on the C57BL/6 background
(MGI Ref ID J:185261)
females progress to blood glucose levels of 333 +/- 46.3 mg/dl by 22 weeks of age
(MGI Ref ID J:185261)
hyperglycemia is more evident in males than females, but after a time delay, also occurs in females
(MGI Ref ID J:106121)
males progress to blood glucose levels of 399 +/- 38.8 mg/dl by 22 weeks of age
(MGI Ref ID J:185261)
mice exhibit hyperglycemia by 8 weeks of age
(MGI Ref ID J:185261)

impaired glucose tolerance
inability to clear plasma glucose following an overnight fast
(MGI Ref ID J:106121)

increased blood urea nitrogen level
increased BUN levels in both male and female mice
(MGI Ref ID J:185261)

increased cholesterol level
increased cholesterol levels in both male and female mice
(MGI Ref ID J:185261)

increased circulating insulin level
mice are hyperinsulinemic by 6 weeks of age but levels decrease as glucose levels rise
(MGI Ref ID J:106121)

increased circulating triglyceride level
(MGI Ref ID J:106121)
increased serum triglyceride levels in both male and female mice
(MGI Ref ID J:185261)

insulin resistance
at 6 weeks of age, most females are insulin resistant; they are hyperinsulinemic while maintaining only moderately elevated glucose levels
(MGI Ref ID J:106121)
by 10 weeks of age, female mice are hyperglycemic while still maintaining high (but insufficient) levels of insulin
(MGI Ref ID J:106121)
by 14 weeks of age, many females have even lower plasma insulin and increasing plasma glucose levels
(MGI Ref ID J:106121)
males show a similar progression of insulin resistance as females but starting at an earlier age, showing high insulin and high glucose at 6 weeks of age
(MGI Ref ID J:106121)

References

Hudkins KL; Pichaiwong W; Wietecha T; Kowalewska J; Banas MC; Spencer MW; Muhlfeld A; Koelling M; Pippin JW; Shankland SJ; Askari B; Rabaglia ME; Keller MP; Attie AD; Alpers CE. 2010. BTBR Ob/Ob mutant mice model progressive diabetic nephropathy. J Am Soc Nephrol 21(9):1533-42PubMed: 20634301 MGI: J:185261
Stoehr JP; Nadler ST; Schueler KL; Rabaglia ME; Yandell BS; Metz SA; Attie AD. 2000. Genetic obesity unmasks nonlinear interactions between murine type 2 diabetes susceptibility loci Diabetes 49(11):1946-54PubMed: 11078464 MGI: J:65486
Stoehr JP; Byers JE; Clee SM; Lan H; Boronenkov IV; Schueler KL; Yandell BS; Attie AD. 2004. Identification of major quantitative trait loci controlling body weight variation in ob/ob mice. Diabetes 53(1):245-9PubMed: 14693723 MGI: J:87998

Additional References
Oler AT; Attie AD. 2008. A rapid, microplate SNP genotype assay for the leptinob allele. J Lipid Res 49(5):1126-9PubMed: 18272929 MGI: J:133040
Lee VK; Hosking BM; Holeniewska J; Kubala EC; Lundh von Leithner P; Gardner PJ; Foxton RH; Shima DT. 2018. BTBR ob/ob mouse model of type 2 diabetes exhibits early loss of retinal function and retinal inflammation followed by late vascular changes. Diabetologia 61(11):2422-2432PubMed: 30094465 MGI: J:269004
Ranheim T; Dumke C; Schueler KL; Cartee GD; Attie AD. 1997. Interaction between BTBR and C57BL/6J genomes produces an insulin resistance syndrome in (BTBR x C57BL/6J) F1 mice. Arterioscler Thromb Vasc Biol 17(11):3286-93PubMed: 9409324 MGI: J:44943
Lan H; Rabaglia ME; Schueler KL; Mata C; Yandell BS; Attie AD. 2004. Distinguishing covariation from causation in diabetes: a lesson from the protein disulfide isomerase mRNA abundance trait. Diabetes 53(1):240-4PubMed: 14693722 MGI: J:88853
Haluzik M; Colombo C; Gavrilova O; Chua S; Wolf N; Chen M; Stannard B; Dietz KR; Le Roith D; Reitman ML. 2004. Genetic background (C57BL/6J versus FVB/N) strongly influences the severity of diabetes and insulin resistance in ob/ob mice. Endocrinology 145(7):3258-64PubMed: 15059949 MGI: J:90742

Additional - Lep^ob related

Technical Support

Contact Technical Support

Genotyping Protocols

Restriction Enzyme Digest: Lep^ob
Pyrosequencing: Lep^ob
End Point Analysis: Lep^ob

Genotyping resources and troubleshooting

Dietary Information

LabDiet® 5K52 formulation (6% fat)

Breeding Considerations

This line is maintained by mating heterozygous mice.

Additional Breeding and Husbandry Support

Mating System

Heterozygote x Heterozygote

Appearance

black and tan, obese, tufted
Related Genotype: a^t/a^t Lep^ob/Lep^ob tf/tf

black and tan, lean, tufted
Related Genotype: a^t/a^t Lep^ob/+ tf/tf

Citation
When using the BTBR obese mouse strain in a publication, please cite the originating article(s) and include JAX stock #004824 in your Materials and Methods section.

Animal Health Reports

Facility Barrier Level Descriptions

AX12 (Maximum)

Pricing & Availability

Available Now

Domestic

International

Live Mouse

Age Genotype Price

weeks

Cryorecovery - Pricing

Service Genotype Price

Heterozygous or wildytpe for Lep<ob>

We will fulfill your order by providing at least two carriers for each strain ordered. The total number, sex, and genotypes provided will vary, although typically 8 or more animals are provided. Please check genotypes which will be recovered. While the genotypes of all animals produced will be communicated to you prior to scheduling shipment, the genotypes of animals provided may not reflect the mating scheme and genotypes described in the strain description. Animals are typically ready to ship in 11-14 weeks. If a second recovery is required to produce the minimum number of animals, then delivery time would increase to approximately 25 weeks. If we fail to produce animals of the correct genotype, you will not be charged. We cannot guarantee the reproductive success of mice shipped to your facility. If the mice are lost after the first three days (post-arrival) or do not produce progeny at your facility, a new order and fee will be necessary.
Cryorecovery to establish a Dedicated Supply for greater quantities of mice. Mice recovered can be used to establish a dedicated colony to contractually supply you mice according to your requirements. Price by quotation.

Payment Terms and Conditions

Terms are granted by individual review and stated on the customer invoice(s) and account statement. These transactions are payable in U.S. currency within the granted terms. Payment for services, products, shipping containers, and shipping costs that are rendered are expected within the payment terms indicated on the invoice or stated by contract. Invoices and account balances in arrears of stated terms may result in The Jackson Laboratory pursuing collection activities including but not limited to outside agencies and court filings.

The Jackson Laboratory's Genotype Promise

The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.

Terms Of Use

Terms of Use

General Terms and Conditions

Questions about Terms of Use

Licensing Information

Phone: 207-288-6470

Email: TechTran@jax.org

JAX® Mice, Products & Services Conditions of Use

"MICE" means mouse strains, their progeny derived by inbreeding or crossbreeding, unmodified derivatives from mouse strains or their progeny supplied by The Jackson Laboratory ("JACKSON"). "PRODUCT(S)" means biological materials supplied by JACKSON, and their derivatives. "SERVICES" means projects conducted by JACKSON for other parties that may include but are not limited to the use of MICE or PRODUCTS. "RECIPIENT" means each recipient of MICE, PRODUCTS, or SERVICES provided by JACKSON including each institution, its employees and other researchers under its control. MICE or PRODUCTS shall not be: (i) used for any purpose other than internal research, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services. Acceptance of MICE, PRODUCTS or SERVICES from JACKSON shall be deemed as agreement by RECIPIENT to these conditions, and departure from these conditions requires JACKSON’s prior written authorization.

No Warranty

MICE, PRODUCTS AND SERVICES ARE PROVIDED "AS IS". JACKSON EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.

Credit for PRODUCTS or SERVICES

In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of, PRODUCTS or SERVICES, JACKSON will, at its option, provide credit or replacement for the PRODUCT received or the SERVICES provided; JACKSON makes no other representations and this shall be the exclusive remedy of the purchaser. Please note specific policy for live mice.

Animal Care and Use for SERVICES

Consistent with the requirement for a written understanding regarding animal care and use, the JACKSON Animal Care and Use Committee will review the animal care and use protocol(s) associated with any SERVICES to be performed at JACKSON, and JACKSON shall have ultimate responsibility and authority for the care of animals while on site or in JACKSON custody.

No Liability

In no event shall JACKSON, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, PRODUCTS, or SERVICES, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of JACKSON, its agents or employees. Unless prohibited by law, in purchasing or receiving MICE, PRODUCTS, or SERVICES from JACKSON, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges JACKSON from all such causes of action or damages, and further agrees to defend and indemnify JACKSON from any costs or damages arising out of any third party claims.

MICE, PRODUCTS or SERVICES are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.

The foregoing represents the General Terms and Conditions applicable to JACKSON’s MICE, PRODUCTS or SERVICES. In addition, special terms and conditions of sale of certain MICE, PRODUCTS, or SERVICES may be set forth separately in JACKSON web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, PRODUCTS and SERVICES by JACKSON, and by its licensees and distributors.

Acceptance of delivery of MICE, PRODUCTS or SERVICES shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on JACKSON, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, PRODUCTS or SERVICES by JACKSON.

Related Strains

All

By Allele

By Gene

By Collection

View All Strains

There are no related strains using this filter.

▲

Stock No: |

Related By:

▼

Overview

Also Known As: BTBR obese

Genetic overview

Lepob

Research Applications

Base Price

Details

Detailed Description

Development

Control Suggestions

Additional Information

Selected References

Genetics

Lepob

Allele Symbol: Lepob

Disease/Phenotype

Disease Terms

Model with phenotypic similarity to human disease where etiologies are distinct. Human genes are associated with this disease. Orthologs of these genes do not appear in the mouse genotype(s).

Models with phenotypic similarity to human diseases where etiology is unknown or involving genes where ortholog is unknown.

Research Areas By Genotype

This mouse can be used to support research in many areas including:

Genotype: Lepob related

Mammalian Phenotype Terms by Genotype

Genotype: Lepob/Lepobinvolves: C57BL/6J

adipose tissue phenotype

cardiovascular system phenotype

cellular phenotype

digestive/alimentary phenotype

endocrine/exocrine gland phenotype

growth/size/body region phenotype

hematopoietic system phenotype

homeostasis/metabolism phenotype

immune system phenotype

integument phenotype

liver/biliary system phenotype

mortality/aging

muscle phenotype

nervous system phenotype

skeleton phenotype

vision/eye phenotype

behavior/neurological phenotype

Genotype: Lepob/LepobB6.Cg-Lep/J

adipose tissue phenotype

behavior/neurological phenotype

integument phenotype

liver/biliary system phenotype

muscle phenotype

neoplasm

nervous system phenotype

renal/urinary system phenotype

reproductive system phenotype

respiratory system phenotype

skeleton phenotype

cardiovascular system phenotype

endocrine/exocrine gland phenotype

growth/size/body region phenotype

hematopoietic system phenotype

homeostasis/metabolism phenotype

immune system phenotype

Genotype: Lepob/LepobD2.Cg-Lep/Chua

endocrine/exocrine gland phenotype

growth/size/body region phenotype

homeostasis/metabolism phenotype

Genotype: Lepob/LepobFVB.Cg-Lep/Chua

homeostasis/metabolism phenotype

Genotype: Lepob/Lepobinvolves: 129X1/SvJ * C57BL/6

adipose tissue phenotype

growth/size/body region phenotype

homeostasis/metabolism phenotype

behavior/neurological phenotype

integument phenotype

liver/biliary system phenotype

renal/urinary system phenotype

reproductive system phenotype

digestive/alimentary phenotype

endocrine/exocrine gland phenotype

Genotype: Lepob/Lep+involves: 129X1/SvJ * C57BL/6

liver/biliary system phenotype

Genotype: Lepob/Lepobinvolves: 129 * C57BL/6

adipose tissue phenotype

Lep^ob

Lep^ob

Allele Symbol: Lep^ob

Genotype: Lep^ob related

Genotype: Lep^ob/Lep^ob
involves: C57BL/6J

Genotype: Lep^ob/Lep^ob
B6.Cg-Lep/J

Genotype: Lep^ob/Lep^ob
D2.Cg-Lep/Chua

Genotype: Lep^ob/Lep^ob
FVB.Cg-Lep/Chua

Genotype: Lep^ob/Lep^ob
involves: 129X1/SvJ * C57BL/6

Genotype: Lep^ob/Lep⁺
involves: 129X1/SvJ * C57BL/6

Genotype: Lep^ob/Lep^ob
involves: 129 * C57BL/6

Genotype: Lep^ob/Lep^ob
BKS.Cg-Lep/J

Genotype: Lep^ob/Lep^ob
B6.Cg-Lep/OlaHsd

Genotype: Lep^ob/Lep⁺
involves: C57BL/6J

Genotype: Lep^ob/Lep^ob
B6.Cg-Lep/JBomTac

Genotype: Lep^ob/Lep^ob
involves: STOCK Mlph a Tgfa Cdh23 Ednrb

Genotype: Lep^ob/Lep^ob
involves: C57BL/6

Genotype: Lep^ob/Lep^ob
involves: BTBR * C57BL/6 * V stock

Genotype: Lep^ob/Lep^ob
B6.Cg-Lep/JRj

Genotype: Lep^ob/Lep^ob
BTBR.Cg-Lep

Genotype: Lep^ob/Lep^ob
BTBR.Cg-Lep/WiscJ

Additional - Lep^ob related